NPM1 and acute myeloid leukemia: The NPM1 mutations identified in a substantial proportion of patients with AML generate highly immunogenic antigens (46), and it has been shown that patients with an intact immune response to NPM1-derived neo-antigens have significantly longer overall survival compared with patients without a response (47).